WO2005099686A1 - Composition ingérable ayant des effets favorisant la production et la libération de peptide associé au gène de la calcitonine - Google Patents

Composition ingérable ayant des effets favorisant la production et la libération de peptide associé au gène de la calcitonine Download PDF

Info

Publication number
WO2005099686A1
WO2005099686A1 PCT/JP2005/003839 JP2005003839W WO2005099686A1 WO 2005099686 A1 WO2005099686 A1 WO 2005099686A1 JP 2005003839 W JP2005003839 W JP 2005003839W WO 2005099686 A1 WO2005099686 A1 WO 2005099686A1
Authority
WO
WIPO (PCT)
Prior art keywords
capsaicin
edible composition
isoflavone
related peptide
calcitonin gene
Prior art date
Application number
PCT/JP2005/003839
Other languages
English (en)
Japanese (ja)
Inventor
Kenji Okajima
Toshiya Toda
Original Assignee
Fujicco Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2004113228A external-priority patent/JP4213617B2/ja
Application filed by Fujicco Co., Ltd. filed Critical Fujicco Co., Ltd.
Publication of WO2005099686A1 publication Critical patent/WO2005099686A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones

Definitions

  • Edible composition having calcitonin gene-related peptide production and release promoting action
  • the present invention relates to an edible composition having a calcitonin gene-related peptide production and release promoting action. More specifically, the present invention relates to the prevention and treatment of gastric mucosal injury, lifestyle-related diseases, obesity, malignant tumors, etc., the prevention and treatment of osteoporosis, the reduction of organ transplant rejection, and the biological invasion of invasive factors such as infection. The present invention relates to an edible composition for preventing and reducing organ damage due to a reaction, and for hair growth. Background art
  • TNF- ⁇ is basically the substance that plays the most important role in host defense in the stress reaction, activates monocytes, neutrophils, vascular endothelial cells, etc., and plays a major role in the expansion of the inflammatory response.
  • ⁇ NF- ⁇ production becomes excessive due to strong and continuous stress', circulatory disorders such as thrombus formation and apoptosis of parenchymal cells may occur.
  • thrombus formation and apoptosis of parenchymal cells may occur.
  • cachexia organ dysfunction and morphological changes are caused, the living body falls into so-called cachexia, and various disease symptoms appear. From this point of view, if many etiologies are regarded as stressors, the reaction to them can be considered to be the pathological condition of the disease and the clinical symptoms.
  • TNF- ⁇ gastric mucosa caused by TNF-. It is also known that increased production of TNF- ⁇ increases the risk of developing lifestyle-related diseases such as diabetes, hypertension, hyperlipidemia and arterial sclerosis, as well as cancer and osteoporosis.
  • a calcitonin gene-related peptide plays an important role in suppressing the production of TNF- ⁇ .
  • the calcitonin gene-related peptide is a peptide consisting of 37 amino acids whose structure is very similar to that of the hormone calcitonin. This gene is on the same gene as the calcitonin gene, and its alternative splicing (alternative splicing) Generated.
  • the calcitonin gene-related peptide inhibits vasodilation, osteoblast proliferation, suppression of osteoclast activation, suppression of appetite, and suppression of NF ⁇ B activity, such as TNF-a. promote apoptosis of inhibiting the production and cancer cells.
  • calcitonin gene-related peptide acts on vascular endothelial cells, NO and, although the production of prostaglandin prostaglandin such as PGI 2 is enhanced, these substances, In addition to the action of blood perfusion, it exerts an inhibitory effect on TNF production and calcitonin gene-related peptide is known to have an important effect on the circulatory system. It has chronotropic and inotropic effects, excretion of NaC1 in the body, coronary vasodilation, and renal blood flow.
  • TNF- ⁇ production also inhibits TNF- ⁇ production and have an anti-inflammatory effect, but at the same time, disrupt organ protection mechanisms. Further, etc. which is one I Ndometashin of non-steroidal anti-inflammatory drugs, TNF-by win suppress a large amount of production of PGE 2 induced by alpha, but to relieve the symptoms of fever and pain and swelling, at the same time Inhibits COX-1, which is required for the production of prostaglandins that are important for organ protection.
  • the calcitonin gene-related peptide suppresses the excessive production of TNF- ⁇ causing the above harm and induces insulin-like growth factor, as described above.
  • Insulin-like growth factor promotes hair follicle growth and is thought to play an important role in the transition from quiescence to anagen in the hair cycle and prolongation of anagen.
  • Non-Patent Document 1 Kenni Okajima, “Biological Invasion and Disease From Single Sepsis to Lifestyle-related Diseases” Hyundai Medical Co., Ltd., 2003
  • Non-Patent Document 2 Harada N, Okajima K, Uchiba ⁇ , Katsuragi ⁇ , Cont ribution of capsaicin—sensitive sensory neurons to stress-induced increa se in gastric tissue levels of prostaglandins in rats, Am J Physiol Ga strointest Liver Physiol, 2003 Jul 31 [Epub ahead of print]
  • Non-Patent Document 3 Vignery A, McCarthy TL, The neuropeptide calcitonin gene— related peptide stimulates insulin-like growth factor 1 product ion by primary fetal rat osteoblasts ⁇ Bone s 1996, Vol 18, No 4, 331-335
  • Non-Patent Document 4 Philpott MP, Sanders DA, Kealey T, Effects of insul in and insulin-like growth factors on cultured human hair follicles: IGF-1 1 at physiologic concentrations is an important regulator of hair follicle growth in vitro, J Invest Dermatol, 1994, Vol 102, No 6, 857-861
  • conventional drugs that have been used to suppress the excessive production of TNF- ⁇ as described above have problems with side effects. Therefore, it cannot be said that it is favorable for human health.
  • an edible composition that does not cause such a problem and has the effect of significantly promoting the production and release of a calcitonin gene-related peptide that plays an important role in suppressing TNF- ⁇ overproduction, etc.
  • the present invention has been made in view of such circumstances, and has an effect of preventing and treating gastric mucosal injury, lifestyle-related diseases, obesity, malignant tumors and osteoporosis, an effect of reducing organ transplant rejection, and an invasive factor such as infection. It is an object of the present invention to provide an edible composition using natural ingredients that have a preventive and alleviating effect on organ damage caused by a biological invasive reaction to the skin, a hair-growth effect, and are gentle to the human body and have no side effects. Disclosure of the invention
  • the present inventors have conducted intensive studies to achieve the above object, and as a result, found that the combination of isoflavones and capsaicin significantly promoted the production and release of calcitonin gene-related peptides. That is, the present invention provides an edible composition having a calcitonin gene-related peptide production and release promoting action of the following (1) to (11).
  • An edible composition comprising isoflavones and force psycin as essential components and having a calcitonin gene-related peptide production and release promoting action.
  • An edible composition for preventing and treating gastric mucosal injury comprising isoflavones and capsaicin as essential components, and having an activity of promoting the production and release of a force / lecitonin gene-related peptide.
  • An edible composition for preventing and treating lifestyle-related diseases which has isoflavone and capsaicin as essential components, and has an activity of promoting the production and release of a power / lecitonin gene-related peptide.
  • An edible composition for obesity prevention and medical treatment which comprises isoflavone and capsaicin as essential components and has an activity of promoting the production and release of force / lecitonin-gene-related peptide.
  • An edible composition for preventing malignant tumor occurrence, preventing recurrence and treating which has isoflavone and capsaicin as essential components and has an action of promoting calcitonin gene-related peptide production and release.
  • An edible composition for the prevention and treatment of osteoporosis comprising isoflavone and force psicin as essential components and having a calcitonin gene-related peptide production and release promoting action
  • An edible composition for reducing organ transplant rejection which has isoflavone and capsaicin as essential components and has a calcitonin gene-related peptide production and release promoting action
  • An edible composition for hair growth comprising isoflavones and capsaicin as essential components, and having an action of promoting calcitonin gene-related peptide production and release.
  • the present inventors have found that, in a water immersion restraint stress gastric mucosal lesion model, sensory nerves stimulated by capsaicin, one of the vanilloid compounds of the pungent component of pepper, that is, the sensory nerves that are sensitive to capsaicin are activated. power calcitonin gene-related base peptide is released, at the same time with the production of TN F- alpha is inhibited, vascular endothelial NO synthase (eNOS) activation, via enhanced production of NO, PG I 2 and PGE
  • eNOS vascular endothelial NO synthase
  • This mechanism of action is used to prevent and treat gastric mucosal injury, lifestyle diseases such as diabetes, hypertension, hyperlipidemia and arteriosclerosis, obesity, malignant tumors, and osteoporosis, and to reduce rejection after organ transplantation.
  • lifestyle diseases such as diabetes, hypertension, hyperlipidemia and arteriosclerosis, obesity, malignant tumors, and osteoporosis
  • ⁇ Effective for preventing and reducing organ damage due to biological invasive reactions to various invasive factors, and for hair growth in male pattern hair loss.
  • the edible composition of the present invention has a special defect in the combination of isoflavone and capsaicin, and contains these components as essential components. With such a configuration, production and release of the calcitonin gene-related peptide can be delicately promoted.
  • the essential components refer to the optional components, which are components that are always contained in the composition, and are not subject to quantitative restrictions.
  • the origin of izoflavone used in the present invention is not particularly limited, and includes, for example, soybean seeds, kakkon-o and foods using them. Above all, soybean hypocotyls are convenient because they contain a large amount of isoflavones. It is also possible to use food such as natto.
  • the above-mentioned isoflavones may be used alone or in combination of two or more in the invention. Because of the high concentration of isoflavones, it is also possible to use extracts of soybeans, soybean foods, soybean hypocotyls, kuzu, etc., and their purified products.
  • the solvent for extracting the isoflavone is not particularly limited, but it is preferable to use water or an alcohol such as ethanol.
  • the method of purification can use a synthetic adsorbent, an ion exchange resin, ultrafiltration, or the like, but is not particularly limited.
  • the extract or the purified liquid may be used as it is, or a concentrated liquid obtained by concentrating them or a powder obtained by drying and extracting the extracted liquid or the purified liquid may be used.
  • the origin of capsaicin used in the present invention is not particularly limited, but it is preferable to use pepper.
  • Nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin are known.
  • the above-mentioned various capsaicins are used alone or in combination of two or more.
  • Pepper can be used as it is after being ground or powdered. However, it is also possible to use an industrially produced pepper extract because of using high concentration of cabsaicin. Pepper extract extracted from pepper with aqueous ethanol, pepper oleoresin extracted mainly from nonpolar to intermediate polar organic solvents such as hexane and ether, and pepper oleoresin are re-extracted with ethanol, and insoluble matter is filtered off. Can be used according to its characteristics.
  • the edible composition of the present invention contains isoflavone and psisaicin obtained as described above as essential components, and a mixture of these may be used directly as it is, but generally, These are used by dissolving or dispersing them in an appropriate liquid carrier or mixing them in an appropriate powder carrier.
  • the content of the isoflavone to be an active ingredient is preferably in the range of 0.001 to 0.5% by weight (hereinafter abbreviated as “%”) in the case of a liquid.
  • the content is preferably in the range of 0.01 to 80%, and in the case of granules, the content is preferably in the range of 0.01 to 40%.
  • the content of the above-mentioned capsaicin as an active ingredient is preferably in the range of 0.001 to 0.05% for liquids, and in the case of powders. Is preferably in the range of 0.001 to 5%, and in the case of granules, it is preferably in the range of 0.001 to 5%.
  • the ratio between the above isoflavone and capsaicin is important, and the isoflavone / capsaicin is preferably contained in a weight ratio of 50,000 O: 1 to 1:10, more preferably isoflavone: capsaicin.
  • Bon: capsaicin 500: 1 to 1: 1 weight ratio range. That is, when both are contained at such a ratio, the synergistic effect of both allows the calcitonin gene-related peptide production and release promoting actions required in the present invention to be effectively obtained. .
  • the edible composition of the present invention is expected not only to humans but also to animals such as pets and livestock, to have the same effect as the above-mentioned effect observed when administered to humans.
  • the above-mentioned mixture of isoflavone and capsaicin can be administered in several divided doses to give a daily dose of 10 to 400 mg.
  • the above mixture is contained in animal feed at a rate of 0.001 to 5%, and a range of 1 to 40 mg / kg body weight per day. It is preferred that it be administered.
  • the edible composition of the present invention having a calcitonin gene-related peptide production and release promoting action is not particularly limited in its shape and eating and drinking method as long as it contains isoflavone and capsaicin as active ingredients as described above. More specifically, it can be used for general foods such as beverages, cooked foods, desserts, confectioneries, dairy products, foods, breads, etc. ⁇ Solid or semi-solid preparations such as tablets, powders, and granules I can give it.
  • Optional ingredients other than isoflavones and capsaicin include, for example, sweeteners, seasonings, acidulants, flavorings such as umami, emulsifiers, dispersants, antioxidants, preservatives, ⁇ thickeners, binders, fragrances, etc.
  • sweeteners seasonings, acidulants, flavorings such as umami, emulsifiers, dispersants, antioxidants, preservatives, ⁇ thickeners, binders, fragrances, etc.
  • excipients, binders, disintegrants, film agents, lubricants, fillers, diluents, pH adjusters, emulsifiers, dispersants examples include stabilizers, flavoring agents, coloring agents, and the like.
  • the above-mentioned five groups consisted of the isoflavone-administered group, the cypressic acid-administered group, the isoflavone + cabsaicin-administered group, and the non-administered group (of the normal diet), as shown in Table 1 below.
  • capsaicin was dissolved in a 10% aqueous ethanol solution containing 10% Tween 20, and orally administered one hour before restraint by water immersion (administration of lmg / kg body weight as capsaicin). Further, in the isoflavone + cabsaicin administration group, both were administered in the same manner as described above.
  • the above five groups namely, a normal group (norma 1; no water immersion restraint), a control group (Control; water immersion restraint) and three test groups (water immersion restraint + isoflavone, water immersion restraint + cabsaicin, water Based on the stomach excised from immersion restraint + isoflavone + capsaicin), the gastric injury index and gastric calcitonin gene-related peptide concentration (CGRP) were measured. The results are shown in Table 1 below. Each data shows the average value of each group.
  • Example 2 administering test for gastric ulcer patients
  • the subjects were those who had endoscopic gastric ulcers and were divided into 4 groups, each group consisting of 4 persons.
  • group 1 of which, isoflavone-containing tablets (isoflavone extract; Fujiflaco P40) were used to administer 4 Omg of isoflavones per day, and in group 2, tablets containing capsaicin were used.
  • the administration resulted in ingestion of lmg of power petitisin per day.
  • Group 3 received tablets containing both, and gnolepe 4 received pseudo tablets. This was done for 20 days.
  • the patient was granted permission for subjective symptoms during the administration period, and after the administration, an endoscopy of the stomach was performed.
  • the results are shown in Table 2 below. Each data shows the average value in each group.
  • the 80-day-old SD female pets divided into 5 groups (6 per group. Of the 5 groups, 4 groups were ovariectomized and 10 days post-excision rats)
  • the animals were fed a standard diet [power deficiency diet (Ca: 0.004%, P: 0.3%)] and the like, and bred for 28 days. After that, they were fasted for 1 ⁇ (18 hours), all rats were sacrificed, and their femurs were removed.
  • the above five groups consisted of the isoflavone-administered group, the capsa ⁇ T-sin-administered group, the isoflavone-capsaicin-administered group, and the non-administered group (standard diet), as shown in Table 3 below. Only) belongs to the misalignment.
  • the isoflavone-administered group in addition to the standard diet, 1% arbor, soybean suspended in an aqueous solution of oral xypropylcellulose was orally administered during the breeding period (the soybean intake was 9 Omg / kg body weight / day. Administration).
  • the 18-week-old male SHRS PZ 1 zm rats were divided into 4 groups of 6 animals per group.
  • Group 1 was fed on a diet supplemented with soybean germ extract (Fujiflavone P40) so that the isoflavone intake was 9 Omg / kg body weight Zday.
  • Group 2 was fed on a diet prepared such that the intake of force psycin was 1 mg Zkg body weight / day.
  • Group 3 received both isoflavone and force psycin.
  • Group 4 was the control group.
  • Tail blood pressure measurement on day 50 of administration 260 ⁇ 5.2 mmHg for group 1, 268 ⁇ 10.4 mmHg for group 2, 246 ⁇ 4.4 mmHg for group 3, and 279 soil for group 4 3.1 mmH (Group 3 was significantly different from Group 4).
  • the measured value of calcitonin gene-related peptide in the blood was highest in group 4 as well. This allows simultaneous administration of isoflavone and capsaicin It can be seen that doing so promotes the production of the calcitoun gene-related peptide and is therefore effective for hypertension.
  • the feed given to each of the above groups consisted of a standard diet (calcium-deficient diet (Ca: 0.004%, P: 0.3%)), isoflavone (0% isoflavone in the standard diet). Feed containing 25%), capsaicin (feed containing 0.005% capsaicin added to the standard diet), isoflavone + capsaicin (feed containing 0.25% isoflavone and 0.005% capsaicin added to the standard diet). Either.
  • a liver metastasis model was created by transplanting a highly metastatic human colon cancer cell line. Ten days after cancer cell transplantation, hepatic ischemia-reperfusion was performed, and the number of metastatic cancer cells was counted thereafter.
  • group 1 of the above 4 groups was bred on a diet supplemented with soybean germ extract (Fujiflavone P40) so that isoflavone intake was 9 OmgZkg g body weight Zday.
  • Gnorape 2 was fed on a diet prepared so that the capsaicin intake was 1 mg / kg body weight / day.
  • Group 3 received both isoflavones and capsaicin, and group 4 was the control group.
  • Liver extirpated from all the prescribed rats divided into 4 gnolops (5 per group) were stored in organ preservation solution for 24 hours, and then transplanted into syngeneic rats. At this time, the lymphocyte of the peripheral blood was separated, and the molecules on the cell surface were analyzed by FACS.
  • group 1 of the above 4 groups should be adjusted so that the amount of isoflavone is 9 Omg / kg body weight / day: a diet supplemented with bean germ extract (Fujiflavon ⁇ 40)
  • Group 2 was fed a diet prepared so that capsaicin intake was lmg / kg body weight / day.
  • Group 3 received both isoflavone and capsaicin
  • group 4 served as a control group, and as a result of the experiment as described above, groups 1 and 2 showed a lower rate of settlement than group 4. It was slightly expensive.
  • Manako and calcitonin gene-related peptides also showed significantly higher levels than the other groups. This shows that simultaneous administration of isoflavone and capsaicin promoted the production of canolecitonin gene-related peptides and reduced the rejection of organ transplantation.
  • Endotoxin 5 mg / kg body weight was intravenously injected to all the predetermined rats divided into 4 groups (5 rats per group), a shock model was prepared, and the blood pressure was measured.
  • soybean germ extract (Fujiflavone P40) was added to Group 1 of the above 4 groups so that the amount of isoflavone was 9 Omg / kg body weight / day.
  • Group 2 was fed a diet prepared so that the capsaicin intake was 1 mg Z kg body weight / day.
  • Group 3 received both isoflavones and capsaicin, and group 4 was the control group.
  • mice purchased at the age of 3 weeks were randomly divided into 4 groups of 1 gnolap and 10 mice. After 1 week of acclimatized breeding, group 1 had a higher isoflavone intake. The animals were reared on a diet supplemented with soybean germ extract (Fujif 4bon P40) so that 9 O mg / kg body weight Z day was obtained. Group 2 was prepared so that capsaicin intake capacity S 2 mg / kg body weight Z day The feed was raised. Group 3 received both isoflavone and capsaicin, and Group 4 served as a control. The hair was cut at the age of 6 weeks, and the state of hair growth was observed. That is, the number of mice whose hair regeneration was completed within 40 days after the start of ingestion of the test feed was measured. The results are shown in Table 5 below.
  • the edible fibrous composition comprising isoflavone and capsaicin as essential components according to the present invention has a function of suppressing the production of inflammatory cytokines such as TNF- ⁇ and the like, which are promoted by social and psychological or physical stress. Promotes the production and release of calcitonin gene-related peptides that have the function of inducing growth-like growth factors, thereby preventing gastric mucosal injury, lifestyle-related diseases, obesity, preventing the occurrence and recurrence of malignant tumors, and preventing osteoporosis. It has preventive and therapeutic effects, has the effect of reducing rejection after organ transplantation, has the effect of preventing and treating organ damage due to invasive reactions after infection, surgery, and trauma, and has the effect of hair growth on the hair.
  • Such an edible composition of the present invention plays a significant role in preventing or treating diseases that are a major problem in modern life, or in overcoming physical complexes. Expected to stand
  • CGRP Calcitonin gene-related peptide (per stomach tissue weight)
  • CGRP Calcitonin gene-related peptide (per bone, tissue weight)
  • CGRP Calcitonin gene-related peptide (per stomach tissue weight)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Une composition ingérable ayant des effets favorisant la production et la libération d'un peptide associé au gène de la calcitonine. Ainsi, une composition ingérable comprenant de l'isoflavone et de la capsaïcine en tant qu'ingrédients principaux et ayant des effets favorisant la production et la libération d'un peptide associé au gène de la calcitonine ; et une composition ingérable comprenant la composition ingérable décrite ci-dessus pour prévenir et traiter les blessures de la muqueuse gastrique, les maladies liées au mode de vie, l'obésité, les tumeurs malignes et l'ostéoporose, les rejets de greffe accompagnant les transplantations d'organes, pour prévenir et soigner les blessures organiques causées par les réactions contre des facteurs invasifs tels que les infections, et pour stimuler la pousse des poils (par exemple, celle des cheveux). Cette composition ingérable exerce des effets de prévention et de traitement des blessures de la muqueuse gastrique, etc., et ces effets sont doux sans risque d'effets secondaires.
PCT/JP2005/003839 2004-04-07 2005-03-01 Composition ingérable ayant des effets favorisant la production et la libération de peptide associé au gène de la calcitonine WO2005099686A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004113228A JP4213617B2 (ja) 2003-10-31 2004-04-07 カルシトニン遺伝子関連ペプチド産生及び放出促進作用を有する、胃粘膜傷害予防・治療用可食性組成物および育毛用可食性組成物
JP2004-113228 2004-04-07

Publications (1)

Publication Number Publication Date
WO2005099686A1 true WO2005099686A1 (fr) 2005-10-27

Family

ID=35149753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/003839 WO2005099686A1 (fr) 2004-04-07 2005-03-01 Composition ingérable ayant des effets favorisant la production et la libération de peptide associé au gène de la calcitonine

Country Status (1)

Country Link
WO (1) WO2005099686A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059523A1 (fr) * 1999-04-08 2000-10-12 Metagenics, Inc. Composition et procede destines au traitement de l'inflammation et des douleurs chez les mammiferes
JP2002275062A (ja) * 2001-02-12 2002-09-25 Warner Lambert Co 核因子カッパｂ媒介の疾患および障害の治療剤
EP1329222A1 (fr) * 2001-12-18 2003-07-23 Daicho Kikaku Incorporated Company Compositions d'isoflavones pour utilisation médicale
JP2003286180A (ja) * 2002-03-28 2003-10-07 Fuji Oil Co Ltd 肥満抑制剤及びそれを含む食品
JP2004059454A (ja) * 2002-07-25 2004-02-26 Japan Energy Corp キナゾリン誘導体及びＮＦ−κＢ活性化阻害剤
JP2005068129A (ja) * 2003-10-31 2005-03-17 Kenji Okajima カルシトニン遺伝子関連ペプチド産生及び放出促進作用を有する可食性組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059523A1 (fr) * 1999-04-08 2000-10-12 Metagenics, Inc. Composition et procede destines au traitement de l'inflammation et des douleurs chez les mammiferes
JP2002275062A (ja) * 2001-02-12 2002-09-25 Warner Lambert Co 核因子カッパｂ媒介の疾患および障害の治療剤
EP1329222A1 (fr) * 2001-12-18 2003-07-23 Daicho Kikaku Incorporated Company Compositions d'isoflavones pour utilisation médicale
JP2003286180A (ja) * 2002-03-28 2003-10-07 Fuji Oil Co Ltd 肥満抑制剤及びそれを含む食品
JP2004059454A (ja) * 2002-07-25 2004-02-26 Japan Energy Corp キナゾリン誘導体及びＮＦ−κＢ活性化阻害剤
JP2005068129A (ja) * 2003-10-31 2005-03-17 Kenji Okajima カルシトニン遺伝子関連ペプチド産生及び放出促進作用を有する可食性組成物

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BAXA D.M. ET AL: "Genistein reduces NF-kappa B in T lymphoma cells via a caspase-mediated cleavage of I kappa B alpha.", BIOCHEMICAL PHARMACOLOGY., vol. 66, 2003, pages 1009 - 1018, XP002989167 *
HARADA N. ET AL: "Contribution of capsaicin-sensitive sensory neurons to stress-induced increases in gastric tissue levels of prostaglandins in rats.", AM J PHYSIOL., vol. 285, December 2003 (2003-12-01), pages G1214 - G1224, XP002989169 *
INOUE D. AND MATSUMOTO T. ET AL: "Hone Taisha Kiso Kenkyu no Shinpo.", JAPANESE JOURNAL OF CLINICAL MEDICINE., vol. 60, 28 March 2002 (2002-03-28), pages 25 - 33, XP002992643 *
MILLET I. ET AL: "Inhibition of NF-kappaB Activity and Enhancement of Apoptosis by the Neuropeptide Calcitonin Gene-related Peptide.", THE JOURNAL OF BIOLOGICAL CHEMSITRY., vol. 275, no. 20, 19 May 2000 (2000-05-19), pages 15114 - 15121, XP002989170 *
PHILPOTT M.P. ET AL: "Effects of Insulin and Insulin-Like Growth Factors on Cultured Human Hair Follicles: IGF-I at Physiologic Concentrations is an Important Regulator of Hairfollicle Growth in Vitro.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY., vol. 102, 1994, pages 857 - 861, XP001095971 *
SINGH S. ET AL: "Capsaicin (8-Methyl-N-Vanillyl-6-Nonenamide) Is a Potent Inhibitor of Nuclear Transcription Factor-KappaB Activator by Diverse Agents.", THE JOURNAL OF IMMUNOLOGY., vol. 157, no. 10, 1996, pages 4412 - 4420, XP002989168 *
VIGNERY A. ET AL: "The Neuropeptide Calcitonin Gene-Related Peptide Stimulates Insulin-like Growth Factor I Production by Primary Fetal Rat Osteoblasts.", BONE., vol. 18, no. 4, April 1996 (1996-04-01), pages 331 - 335, XP002065011 *

Similar Documents

Publication Publication Date Title
JP5334448B2 (ja) グルタチオン産生促進剤およびグルタチオンの欠乏に起因する疾患の予防・治療剤
JP4669920B2 (ja) 血糖上昇抑制且つ血圧上昇抑制作用を有する機能性素材
JP7330471B2 (ja) 線維症の予防、改善または治療のためのｃｈｐ（シクロ－ヒスプロ）の用途
JP4213617B2 (ja) カルシトニン遺伝子関連ペプチド産生及び放出促進作用を有する、胃粘膜傷害予防・治療用可食性組成物および育毛用可食性組成物
KR101170874B1 (ko) 백지 추출물 또는 임페레이토린을 함유하는 소포체 스트레스 완화 또는 미토콘드리아 기능개선용 조성물
KR102127712B1 (ko) 괴각 추출물을 유효성분으로 함유하는 여성 갱년기 질환의 예방 및 치료용 조성물
JP5403942B2 (ja) グルタチオン産生促進剤およびグルタチオンの欠乏に起因する疾患の予防・治療剤
KR101727506B1 (ko) Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
JPWO2006135084A1 (ja) 脂肪性肝炎または脂肪肝の予防または治療薬
KR102519649B1 (ko) 캠퍼롤 및 에피카테킨 갈레이드를 포함하는 홍경천 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물
JP2010106024A (ja) 癌治療及び予防用薬学的組成物、これを含む癌改善並びに予防用健康機能食品
KR20210036293A (ko) 유청단백 가수분해물을 유효성분으로 함유하는 근감소증의 개선, 예방 또는 치료용 조성물
JP2007291014A (ja) カルシトニン遺伝子関連ペプチド産生及び放出促進作用を有する可食性組成物
WO2005099686A1 (fr) Composition ingérable ayant des effets favorisant la production et la libération de peptide associé au gène de la calcitonine
JP6417576B2 (ja) 大豆種子抽出物、該大豆種子抽出物を製造するための方法及びその使用
CN108904481B (zh) 邻羟基查尔酮类似物在制备抗氧化药物中的应用
JP6045369B2 (ja) 一酸化窒素産生抑制剤
WO2020066484A1 (fr) Composition contenant de l'acide ellagique
JP2008115163A (ja) アディポネクチン産生増強・促進剤
KR20180062682A (ko) 인진쑥 수용성 추출물, 그 용도 및 제조 방법
JP7271016B2 (ja) 骨損失疾患の予防、改善または治療のためのｃｈｐ（シクロ－ヒスプロ）および副甲状腺ホルモンを含む組成物の用途
JP2014101329A (ja) 抗炎症剤
JP2019178129A (ja) 血液脳関門保護剤
JP2011032256A (ja) 薬用ニンジンを始めとしたサポニン含有生薬服用時に生じるメンゲン反応の防止及び生薬の吸収性を増大させる製法（生薬の有効成分を鶏卵タンパクに吸収させる方法）による医薬組成物及び健康食品
KR101980809B1 (ko) 귀리껍질 추출물을 포함하는 췌장암의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase